European Medicines Agency sets virus strains for 2026/2027 seasonal flu vaccines
The European Medicines Agency published updated recommendations specifying which influenza virus strains manufacturers should include in seasonal flu vaccines for the 2026/2027 season starting in autumn 2026. The guidance, updated on 17 November 2026 to add recommendations for nucleic acid or mRNA vaccines, relies on monitoring data from the World Health Organization. Flu viruses change continuously, so regular replacement of strain components is necessary to keep vaccines effective. EMA selected specific virus strains for egg-based, cell-based, live-attenuated, and mRNA vaccines. Notably, the recommendations exclude the B/Yamagata virus strain, which surveillance shows has not been detected in global circulation since March 2020. For ordinary readers, these updates explain how European health regulators adjust annual flu shots to match actively spreading viruses. The agency recommended that marketing authorisation holders submit applications to update centrally authorised vaccines by 15 June 2026.
What was announced
The European Medicines Agency (EMA) issued updated recommendations for the influenza virus strains that vaccine manufacturers should include in seasonal flu vaccines for the 2026/2027 season. EMA's Committee for Medicinal Products for Human Use (CHMP) endorsed the initial recommendations in March 2026. EMA amended the text on multiple dates, concluding with a 17 November 2026 update that added guidance for mRNA influenza vaccines and updated vaccine standardisation reagents.
For live-attenuated and egg-based vaccines, EMA recommends:
- An A/Missouri/11/2025 (H1N1)pdm09-like virus
- An A/Darwin/1454/2025 (H3N2)-like virus
- A B/Tokyo/EIS13-175/2025 (B/Victoria lineage)-like virus
For cell-based and nucleic acid-based (mRNA) vaccines, EMA recommends:
- An A/Missouri/11/2025 (H1N1)pdm09-like virus
- An A/Darwin/1415/2025 (H3N2)-like virus
- A B/Pennsylvania/14/2025 (B/Victoria lineage)-like virus
The guidance drops the B/Yamagata lineage strain from standard recommendations, matching WHO recommendations. B/Yamagata has not been detected in global surveillance since March 2020. Where quadrivalent inactivated vaccines are still required during local transitions, manufacturers can include a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.
What it means
Flu viruses change constantly. Regular updates to the strains contained in seasonal flu vaccines ensure that the vaccines match circulating viruses.
Removing B/Yamagata reflects global surveillance data showing the strain is no longer a public health threat. This allows vaccines to focus on active strains. EMA set a deadline of 15 June 2026 for marketing authorisation holders to submit application changes for centrally authorised seasonal flu vaccines.
What the announcement does not tell us
The announcement does not state when updated vaccines will become available to patients in EU member states. It does not list specific vaccine brand names, pricing details, or manufacturing targets. Additionally, the announcement does not identify which specific countries or regions still require quadrivalent vaccines while transitioning to trivalent options.
How this was written
This analysis was written with AI from the official announcement below, using only facts that announcement states. The quoted wording is European Medicines Agency News’s own. Always check the original before acting on anything here.
The recommendations were updated and published on the following dates: 17 November 2026: to include a recommendation for mRNA (nucleic acid) influenza vaccines. Annex I…
Opens www.ema.europa.eu
This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.